Stockscreener 앱 받기
135.77
2.04%
2.71
시간 외 거래:
136.01
0.24
+0.18%
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Gilead Sciences stock may move 4.3% on August earnings report By Investing.com - Investing.com South Africa
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Benzinga
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Gilead Sciences Inc (GILD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gilead uses humor, relatability in ‘Up to Date’ HIV prevention push - Fierce Pharma
GILD|Gilead Sciences Inc|Price:131.549|Chg%:+1.029 - TradingKey
Gilead Sciences (GILD) Gets a Hold from RBC Capital - The Globe and Mail
Laverne Cox Presents Gilead With Excellence in Corporate Philanthropy Award | Social Impact Summit - The Hollywood Reporter
Preventing Those Living with HIV from Navigating the Journey Alone: Henrique’s Commitment - Gilead Sciences
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
J&J, Gilead among recipients of EU drug recommendations this week - Seeking Alpha
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors - ChartMill
Why Investors Are Watching Bristol Myers Squibb, Gilead Sciences and Amgen - Kalkine Media
Gilead’s Trodelvy gets EU panel backing for breast cancer combo By Investing.com - Investing.com Canada
in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer - Business Wire
EU panel recommends Trodelvy-Keytruda after 35% lower progression-or-death risk - Stock Titan
GILD|Gilead Sciences Inc|Price:129.310|Chg%:-1.550 - TradingKey
Gilead Sciences stock trades steady as HIV and oncology pipeline supports long term growth - AD HOC NEWS
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise? - Yahoo Finance
ETFs Investing in Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Stocks - TradingView
How Gilead Is Working With Cultural Influencers to Bring Attention to HIV Stigma and Elevate HIV Prevention - IMDb
Gilead, Merck weekly HIV pill maintains suppression in Phase III switch studies - The Pharma Letter
Why Is Gilead Sciences (NASDAQ:GILD) Trending on the Nasdaq? - Kalkine Media
[AIDS 2026] [Press release] Gilead & Meck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy - European AIDS Treatment Group
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026 - Yahoo! Finance Canada
Gilead Sciences to release Q2 2026 results on August 4 - scanx.trade
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
Gilead and Merck report weekly HIV trial results - grafa.com
GILD Downgraded by Leerink Partners -- Price Target Lowered to $127 - GuruFocus
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Benzinga
Preferred dividends of Gilead Sciences, Inc. – BCS:GILDCL1 - TradingView
Gilead to present HIV prevention and treatment data at AIDS 2026 - Investing.com Canada
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure - Business Wire
Press Release: Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Moomoo
Gilead Sciences' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More - 24/7 Wall St.
Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike… - marketscreener.com
Gilead Sciences stock trades steady as HIV and oncology pipeline supports outlook - Ad-hoc-news.de
Lobbying Update: $1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Benzinga
Gilead Sciences (GILD) Downgraded by Leerink Partners Amid Marke - GuruFocus
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Gilead Sciences stock trades steady as HIV and oncology pipeline underpins recent earnings - Ad-hoc-news.de
Gilead Sciences stock trades steady as HIV and oncology portfolio supports earnings trajectory - ad-hoc-news.de
Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates - Seeking Alpha
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Gilead Built Its Foundation On HIV; Is It Now In Trouble? - Investor's Business Daily
With Up To Date campaign, Gilead brings HIV prevention into the dating conversation - Medical Marketing and Media
Gilead Sciences synthesizes new KRAS mutant inhibitors - BioWorld News
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock By Investing.com - Investing.com South Africa
Gilead Sciences stock trades steadily as oncology progress and HIV franchise support valuation - ad-hoc-news.de
Form 4 Gilead Sciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock By Investing.com - Investing.com South Africa
Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences In - GuruFocus
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock - Investing.com
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv - GuruFocus
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock - Investing.com
Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan - Stock Titan
1.59%
자본화:
|
볼륨(24시간):